Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Rhea-AI Summary
Cadrenal Therapeutics (Nasdaq: CVKD) will participate in the virtual Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The company will deliver a webcast presentation and hold one-on-one investor meetings.
The webcast is scheduled for 9:30 a.m. ET and will be available for replay.
Positive
- None.
Negative
- None.
News Market Reaction – CVKD
In the May 20 session, CVKD gained 3.82%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 results & Phase 3 plan | Positive | -2.4% | Q1 2026 results and detailed Phase 3 CAD-1005 development update. |
| Apr 30 | End-of-Phase 2 outcome | Positive | +19.3% | Completed End-of-Phase 2 FDA meeting and Phase 3 registration path. |
| Mar 31 | FY results & CAD-1005 | Positive | +20.5% | Q4 and full-year results plus CAD-1005 program and FDA feedback. |
| Mar 12 | 12-LOX obesity research | Positive | -8.0% | Preclinical 12-LOX data in obesity and Type 2 diabetes inflammation. |
| Mar 02 | Platform expansion update | Positive | +1.2% | Expansion of 12-LOX inhibitor platform and blinded Phase 2 CAD-1005 data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with positive clinical or strategic content has produced mixed reactions, with 3 aligned positive moves and 2 negative divergences, suggesting inconsistent trading response to updates.
Over the last several months, Cadrenal has focused on CAD-1005 for heparin-induced thrombocytopenia, progressing from an End-of-Phase 2 FDA meeting on Mar 26, 2026 to a planned pivotal Phase 3 trial targeting an NDA in 2029. Financial updates on Mar 31 and May 7, 2026 highlighted operating losses and limited cash, alongside new financing. Against this backdrop, the Lytham Partners Spring 2026 investor conference appearance primarily serves as an investor-relations touchpoint rather than a defined clinical or regulatory milestone.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
Company Webcast
The webcast presentation will take place at 9:30 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at https://app.webinar.net/DxpqArQk70e. The webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/spring2026invreg/.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also in development for chronic indications.
The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and left ventricular assist devices, and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings.
For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.
For more information, please contact:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
